Biotech Unusual Volume: Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Recro Pharma (NASDAQ:REPH), StemCells (NASDAQ:STEM), Actinium Pharmaceuticals (NYSEMKT:ATNM), Agenus (NASDAQ:AGEN)

Posted by on Jun 27, 2014

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from two Phase 3 studies of lumacaftor in combination with ivacaftor that showed statistically significant improvements in lung function (percent predicted forced expiratory volume in one second, or ppFEV1) in people ages 12 and older with cystic fibrosis (CF) who have two copies (homozygous) of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) net profit margin is -36.90% and weekly performance is 44.16%. On last trading day company shares ended up $93.17. Analysts mean target price for the company is $90.45. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) distance from 50-day simple moving average (SMA50) is 34.48%.

Recro Pharma, Inc. (NASDAQ:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, on 17 June announced dosing of the first patient in a Phase IIb clinical trial of Dex-IN in patients undergoing bunionectomy surgery. Recro Pharma Inc. (NASDAQ:REPH) shares fell -0.50% in last trading session and ended the day on $7.91. REPH return on assets is -111.70%.Recro Pharma Inc. (NASDAQ:REPH) quarterly performance is 10.63%.

StemCells Inc. (NASDAQ:STEM) on June 23 announced that President and CEO Martin McGlynn will be a panelist at the 2014 BIO International Convention on June 25, 2014 at 4:15 pm PDT. Mr. McGlynn will participate in the panel discussion, “How International Collaboration is Accelerating the Field.” StemCells Inc. (NASDAQ:STEM) shares moved down -4.25% in last trading session and was closed at $2.03, while trading in range of $1.99 – $2.19. StemCells Inc. (NASDAQ:STEM) year to date (YTD) performance is 65.04%.

Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) announced that it has priced public offering of 1.67 million shares of its common stock at a price to the public of $7.50 per share. In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about June 30, 2014, subject to customary closing conditions. Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) ended the last trading day at $7.06. Company weekly volatility is calculated as 10.29% and price to cash ratio as 30.59.Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) showed a negative weekly performance of -33.27%.

Agenus Inc. (NASDAQ:AGEN) announced promising Phase 2 results for HerpV, a synthetic vaccine candidate for the treatment of patients with genital Herpes Simplex Virus-2 (HSV-2). HerpV contains a defined mixture of peptides representing HSV-2 antigens plus Agenus’ QS-21 Stimulon® adjuvant. Agenus Inc. (NASDAQ:AGEN) weekly performance is 5.93%. On last trading day company shares ended up $3.57. Analysts mean target price for the company is $7.00. Agenus Inc. (NASDAQ:AGEN) distance from 50-day simple moving average (SMA50) is 21.81%.

Leave a Reply

Your email address will not be published. Required fields are marked *